Media and Communications



Thursday, December 11, 2014
Teva Provides 2015 Business Outlook

JERUSALEM--(BUSINESS WIRE)--Dec. 11, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) provides its current outlook for non-GAAP financial performance for the year ending December 31, 2015. In an effort to enhance investor understanding of the Company’s business performance, and to provide more clarity and transparency regarding its projections for 2015, the following assumptions will apply to the 2015 non-GAAP financial outlook: Compared to 2014, foreign exchange rate fluctuations are expected to Read More »

Thursday, December 04, 2014
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)

MHRA and other EU Member States Issue Positive Assessment Report under the Decentralized Procedure for New, Three-Times-A-Week COPAXONE® 40 mg/ml Formulation JERUSALEM--(BUSINESS WIRE)--Dec. 4, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE® (glatiramer acetate) 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis (RMS). The outcome follows a Positive As Read More »

Monday, December 01, 2014
Teva Announces Launch of Generic Exforge HCT® Tablets in the United States

JERUSALEM--(BUSINESS WIRE)--Dec. 1, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Exforge HCT® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets in the United States. Teva was first to file, opening the generic market for the product, as well as making the product eligible for 180 days of marketing exclusivity. Exforge HCT ® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets, marketed by Novartis Pharmaceuticals, had annual sales of approximately $1 Read More »

Wednesday, November 26, 2014
Prof. Yitzhak Peterburg Elected Chairman of Teva’s Board of Directors

Dr. Sol J. Barer joins the Board JERUSALEM--(BUSINESS WIRE)--Nov. 26, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the Board of Directors has elected Professor Yitzhak Peterburg as Chairman, effective January 1, 2015. Prof. Peterburg, a member of the Board since 2012 and from 2009-2010, will succeed Dr. Phillip Frost, who previously announced plans to step down as Chairman by the end of the year. Dr. Frost has also informed the Board that he will not stand for reelection as a director at the upco Read More »

Friday, November 07, 2014
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Late Stage Data from Multiple Studies Showcase Safety and Efficacy Profile JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia Read More »

Friday, November 07, 2014
Teva Presents Positive Safety and Efficacy Data for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis

Late Stage Data to be Presented at ACAAI 2014 JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL® (beclomethasone dipropionate) Nasal Aerosol 80 μg/day in children 4-11 years of age with perennial – or “year round” – allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhiniti Read More »

Tuesday, November 04, 2014
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington’s Disease Trial

ARPEGGIO and LEGATO-HD trials will further evaluate the effect of laquinimod in neurodegenerative diseases JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Nov. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patie Read More »

Wednesday, October 08, 2014
Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets

Comprehensive clinical development program, including nasal and oral HAL studies,support NDA submission for investigational pain medication formulated with Teva’s proprietary abuse deterrence technology JERUSALEM--(BUSINESS WIRE)--Oct. 8, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potentia Read More »

Monday, October 06, 2014
Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas

- Affirms its long-term commitment to being a world-leader in Central Nervous System and Respiratory - - Maintains its current commercial presence but stops Research & Development in other therapeutic areas, including Oncology and Women's Health - JERUSALEM--(BUSINESS WIRE)--Oct. 6, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the results of its strategic review of core therapeutic areas for the Company. The review included an extensive evaluation of Teva’s current and futur Read More »

Monday, September 08, 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia

New Phase III data presented at European Respiratory Society Congress (ERS) builds on recent exacerbation reduction data, creating a special efficacy profile for reslizumab Reslizumab shown to significantly improve lung function and asthma control Findings support reslizumab benefits specifically for moderate to severe asthma patients with elevated level of blood eosinophils JERUSALEM--(BUSINESS WIRE)--Sep. 8, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced Read More »